Genomic BRCA and Extensive ovArian Cancer Testing

This is a prospective observational French multicenter cohort in patients with ovarian and/or primitive peritoneal and/or fallopian tubes carcinoma, histologically confirmed, with an advanced stage at diagnosis (stage III to IV FIGO 2014). The objective is to constitute a clinico-biological database that allows to correlate clinical and progressive features of ovarian cancer patients based on tumor genomics and molecular detected abnormalities.

Inclusion Criteria: * Patient older than 18 years. * Patient with ovarian and/or primitive peritoneal and/or fallopian tubes carcinoma, histologically confirmed, with an advanced stage at diagnosis (stage III to IV FIGO 2014) * Patient in first line therapy * Available tumor sample fixed in formalin and included in paraffin (FFPE): * in pre-chemotherapy, insofar as possible * having a sufficient tumor surface, with a final cellularity of at least 20% * Identification of a molecular genetics' cancer platform participant in GREAT and an onco-geneticists team working with the investigator team * Patient consenting her data to be collected and submitted through an automated processing * Patient beneficiary from the French social security Exclusion Criteria: * Patient with a mucinous ovarian carcinoma * Patient pregnant or breastfeeding * Patient under legal protection (guardianship or court order) or unable to consent